143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial.

Gautschi, O; Li, Q; Matter-Walstra, K; Betticher, D; Frueh, M; Rauch, Daniel; Pless, M; Froesch, P; Mach, N; Ochsenbein, Adrian (2016). 143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial. Journal of thoracic oncology, 11(4Suppl), S120-S120. Elsevier 10.1016/S1556-0864(16)30253-2

[img] Text
1-s2.0-S1556086416302532-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (69kB)
[img]
Preview
Text
accepted_manuscript.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (6MB) | Preview

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Rauch, Daniel, Ochsenbein, Adrian

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1556-1380

Publisher:

Elsevier

Language:

English

Submitter:

Marianne Zahn

Date Deposited:

27 Dec 2016 15:29

Last Modified:

05 Dec 2022 15:00

Publisher DOI:

10.1016/S1556-0864(16)30253-2

PubMed ID:

27198283

BORIS DOI:

10.7892/boris.92046

URI:

https://boris.unibe.ch/id/eprint/92046

Actions (login required)

Edit item Edit item
Provide Feedback